We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for selpercatinib (Eli Lilly Australia Pty Ltd)
Active ingredients
selpercatinib
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Immediate release capsule
Indication
For the treatment of medullary thyroid cancer
Therapeutic area
Oncology